CRO-67 / Noxopharm - LARVOL DELTA

CRO-67 has anti-cancer activity in pancreatic tumor cells and stromal cancer-associated fibroblasts. (PubMed, Sci Rep) - "CRO-67 treatment of orthotopic PDAC tumors in mice significantly reduced tumor growth in tumors with active growth (> 150% growth at endpoint), and remodeled tumor stroma (reduced αSMA+ CAF frequency, loosened tumor fibrosis and normalized tumor vasculature). Finally, CRO-67 sensitized PDAC cells to multiple standard-of-care chemotherapeutics in vitro, paving the way for future combination therapy development and validation."

Journal • Fibrosis • Immunology • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • CAFs

Noxopharm soars as CRO-67 reduces pancreatic tumours and barrier cells in complex studies (Investing.com) - "Noxopharm Ltd...has soared on new data regarding its CRO-67 preclinical drug for pancreatic cancer that shows significantly reduced pancreatic tumours and barrier cells in a complex model....The new data from a highly sophisticated study that tested CRO-67 in a complex model, in which human pancreatic cancer cells as well as barrier cells were transplanted into the pancreas of mice, showed a significant decrease in metastatic cancer spread....The study had three major results: Significant decrease in tumour volume growth rate; Significant decrease in barrier cells; and Significant reduction in cancer spread."

Preclinical • Gastrointestinal Cancer • Oncology • Pancreatic Cancer • Solid Tumor

Orphan Designation: Treatment of pancreatic cancer (FDA) - Date Designated: 10/02/2023

Orphan drug • Gastrointestinal Cancer • Oncology • Pancreatic Cancer • Solid Tumor

Latest CRO-67 data shows success in reducing cancer growth (Noxopharm Press Release) - "Innovative biotech...announces that further encouraging data from its Chroma™ platform has been presented at the American Association of Cancer Research (AACR) Special Conference on Pancreatic Cancer...The new results arise from a study that involved human pancreatic cancer tumour cells being implanted under the skin into mice. The mice were then treated with CRO-67 for 21 days, with tumour volume measured over this dosing period....At the end of drug treatment, CRO-67 significantly reduced tumour volume in vivo by an average of 56.7% versus the untreated controls (p=0.0013)."

Preclinical • Gastrointestinal Cancer • Oncology • Pancreatic Cancer • Solid Tumor